Cargando…

TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy

TAFRO syndrome is defined by the presence of thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis/renal dysfunction (R), and organomegaly (O) and can be seen with idiopathic multicentric Castleman disease (iMCD) or as an isolated process without iMCD. Although the diagnosis of iMCD in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Corinne, Phillips, Alexis, Aggarwal, Vikram, Slonim, Liron Barnea, Fajgenbaum, David C., Karmali, Reem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525304/ https://www.ncbi.nlm.nih.gov/pubmed/34720942 http://dx.doi.org/10.1159/000518079

Ejemplares similares

A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome
por: Ük, Ece, et al.
Publicado: (2022)

Multicentric Castleman disease with TAFRO syndrome and Sjögren's
por: Li, Zi Ying, et al.
Publicado: (2019)

Castleman disease and TAFRO syndrome
por: Masaki, Yasufumi, et al.
Publicado: (2022)

Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan
por: Masaki, Yasufumi, et al.
Publicado: (2019)

Castleman disease, TAFRO syndrome, idiopathic plasmacytic lymphadenopathy, and autoimmune disease
por: Nakamura, Naoya
Publicado: (2022)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis
por: Nishimura, Yoshito, et al.
Publicado: (2022)

The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s disease
por: Kubokawa, Ikuko, et al.
Publicado: (2014)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
por: Pierson, Sheila K., et al.
Publicado: (2022)

TAFRO Syndrome – A Specific Subtype of Castleman's Disease in China
por: Ma, Wan-Lu, et al.
Publicado: (2018)

Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key
por: Zhou, Qian-Yun
Publicado: (2022)

Castleman's disease with TAFRO syndrome: a case report from Syria
por: Alhoulaiby, Sami, et al.
Publicado: (2017)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Increased mTORC2 pathway activation in lymph nodes of iMCD‐TAFRO
por: Phillips, Alexis D., et al.
Publicado: (2022)

Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine
por: Hoffmann, Christian, et al.
Publicado: (2022)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

A Patient With Human Herpesvirus 8-Positive Multicentric Castleman’s Disease Who Met Criteria for TAFRO Syndrome: Controversy in Practice?
por: Fuentes-Lacouture, Maria Cynthia, et al.
Publicado: (2020)

Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports
por: Ferrero, Simone, et al.
Publicado: (2021)

Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura
por: Sood, Ruchi, et al.
Publicado: (2013)

Idiopathic Multicentric Hyaline Vascular-Type Castleman Disease
por: Moutinho, Adelaide, et al.
Publicado: (2021)

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease
por: Nabel, Christopher S., et al.
Publicado: (2019)

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease
por: Nishikori, Asami, et al.
Publicado: (2022)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
por: Kosmidis, Christoforos S., et al.
Publicado: (2022)

Genetic basis for iMCD-TAFRO
por: Yoshimi, Akihide, et al.
Publicado: (2020)

Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience
por: Owattanapanich, Weerapat, et al.
Publicado: (2018)

P1733: NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET
por: Mukherjee, S., et al.
Publicado: (2022)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature
por: Louis, Céline, et al.
Publicado: (2017)

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
por: Rossi, Jean-Francois, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Cutaneous plasmacytosis: A rare initial presentation of idiopathic multicentric Castleman's disease
por: Yamamoto, Yu, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease Presenting With Hypertensive Choroidopathy: A Case Report
por: Mimoto, Tamami, et al.
Publicado: (2023)

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
por: Tomioka, Yasuaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_obliacmfurju0joo6as6fsge8p